Trial Profile
A Study of Galantamine HBr as an Adjunctive Treatment to Atypical Antipsychotic Medications in Outpatients With Schizophrenia and Associated Cognitive Deficits.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Galantamine (Primary)
- Indications Cognition disorders; Schizophrenia
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 08 Apr 2010 New trial record